BioMerieuxSTU:EYWN +1.51%84 Pretax Margin % is 15.42% as of Dec. 2025, which is 18% above its 10-year median of 13.11. GuruFocus rates STU:EYWN with a GF Score™ of 84/100 and a GF Value™ of €109.28 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, BioMerieux ranks better than 78.22% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. BioMerieux's Pre-Tax Income for the
six
months ended in Dec. 2025 was €313 Mil. BioMerieux's Revenue for the
six
months ended in Dec. 2025 was €2,026 Mil. Therefore, BioMerieux's pretax margin for the quarter that ended in Dec. 2025 was 15.42%.
The historical rank and industry rank for BioMerieux's Pretax Margin % or its related term are showing as below:
STU:EYWN'
s Pretax Margin % Range Over the Past 10 Years
Min: 11.91 Med: 13.11 Max: 22.94
Current: 12.92
STU:EYWN's Pretax Margin % is ranked better than 78.22% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs STU:EYWN: 12.92
BioMerieux (STU:EYWN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BioMerieux Pretax Margin % Related Terms
BioMerieux Pretax Margin % Historical Data
* Premium members only.
The historical data trend for BioMerieux's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EYWN vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, BioMerieux's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BioMerieux's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMerieux (STU:EYWN) has a Pretax Margin % of 15.42% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioMerieux and its competitors. This is 18% above median its historical median of 13.11. Over the past decade, BioMerieux's Pretax Margin % has ranged from 11.91 to 22.94. According to the industry distribution chart, BioMerieux ranks #44 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 21.8%.
Is BioMerieux's Pretax Margin % too high?
BioMerieux's current Pretax Margin % of 15.42% is 18% above median its 10-year median of 13.11. Over the past 10 years, this metric has ranged from a low of 11.91 to a high of 22.94. Based on the distribution chart, BioMerieux ranks #44 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BioMerieux has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #44 out of 202 companies for Pretax Margin %. This places BioMerieux in the top 22% of its industry — outperforming the majority of peers. Historically, BioMerieux's own Pretax Margin % has ranged from 11.91 to 22.94 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioMerieux and its competitors. BioMerieux's current Pretax Margin % is 15.42%, which is 18% above median its own 10-year median of 13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (STU:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €109.28, compared to a current price of €70.75 — trading 35.3% below its estimated fair value. The current Pretax Margin % is 15.42%, which is 18% above median its 10-year median of 13.11. BioMerieux's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BioMerieux (STU:EYWN), the current Pretax Margin % is 15.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (STU:EYWN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €70.75 is trading 35.3% below its estimated GF Value™ of €109.28.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for STU:EYWN:
Pretax Margin %: 15.42% (18% above median its 10-year median of 13.11)
GF Value™: €109.28 vs. price of €70.75 (35.3% below fair value)
No single metric tells the full story. See the STU:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
84GF Score
Get the complete analysis for STU:EYWN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EYWN has been successfully added to your 
